Skip to main content
    I

    Iradimed Co (IRMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $84.84
    -0.51 (-0.60%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Iradimed Co (IRMD) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Iradimed (IRMD) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Iradimed reported EPS of $0.51, below the $0.52 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +38.20%

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.61
    Range$0.58 - $0.64
    5 analysts
    Revenue Consensus
    $25.87M
    Range$24.50M - $27.41M
    5 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.58
    Range$0.56 - $0.61
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.59-1.7%
    60d ago$0.59-1.7%
    30d ago$0.60-3.3%
    7d ago$0.60-3.3%
    Current$0.58
    Revenue Consensus
    $24.95M
    Range$24.10M - $25.80M
    2 analysts

    Next Report

    IRMD has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.0% above the $0.54 reported for the quarter ended Dec 31, 2025.

    IRMD Earnings Call

    The latest IRMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IRMD beat 33, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $24.20M, up 14.2% from $21.20M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.51$0.52N/A-1.92%Miss+8.5%31 up, 0 downOct 30, 2026$24.20M
    Jun 30, 2026$0.41$0.42N/A-2.38%Miss-16.3%20 up, 1 downJul 31, 2026$20.47M
    Mar 31, 2026$0.49$0.45$0.44 - $0.45+8.89%Beat+16.7%20 up, 1 downMay 1, 2026$21.98M
    Dec 31, 2025$0.54$0.48$0.47 - $0.49+12.50%Beat+35.0%20 up, 0 downFeb 10, 2026$22.69M
    Sep 30, 2025$0.47$0.46$0.45 - $0.46+2.17%Beat+9.3%20 up, 0 downNov 3, 2025$21.20M
    Jun 30, 2025$0.49$0.44$0.42 - $0.45+11.36%Beat+16.7%21 up, 1 downAug 1, 2025$20.41M
    Mar 31, 2025$0.42$0.41$0.39 - $0.43+2.44%Beat+16.7%21 up, 1 downMay 5, 2025$19.51M
    Dec 31, 2024$0.40$0.41N/A-2.44%Miss+2.6%21 up, 0 downFeb 13, 2025$19.39M
    Sep 30, 2024$0.43$0.39$0.38 - $0.39+10.26%Beat0.0%20 up, 0 downOct 31, 2024$18.33M
    Jun 30, 2024$0.42$0.37$0.36 - $0.37+13.51%Beat+16.7%20 up, 0 downAug 1, 2024$17.93M
    Mar 31, 2024$0.36$0.34$0.33 - $0.34+5.88%Beat+20.0%20 up, 1 downMay 2, 2024$17.60M
    Dec 31, 2023$0.39$0.38$0.38 - $0.41+2.63%Beat+21.9%30 up, 0 downFeb 8, 2024$17.45M
    Sep 30, 2023$0.43$0.37$0.36 - $0.37+16.22%Beat+48.3%30 up, 0 downNov 3, 2023$16.50M
    Jun 30, 2023$0.36$0.31$0.30 - $0.32+16.13%Beat+38.5%30 up, 0 downAug 3, 2023$16.13M
    Mar 31, 2023$0.30$0.27$0.26 - $0.32+11.11%Beat+36.4%30 up, 0 downMay 4, 2023$15.48M
    Dec 31, 2022$0.32$0.31$0.29 - $0.31+3.23%Beat-3.0%21 up, 0 downFeb 2, 2023$14.86M
    Sep 30, 2022$0.29$0.24$0.24 - $0.25+20.83%Beat+26.1%20 up, 0 downNov 3, 2022$13.41M
    Jun 30, 2022$0.26$0.24$0.23 - $0.24+8.33%Beat+85.7%20 up, 0 downJul 29, 2022$12.72M
    Mar 31, 2022$0.22$0.21$0.20 - $0.21+4.76%Beat+69.2%20 up, 0 downApr 29, 2022$12.31M
    Dec 31, 2021$0.33$0.21$0.21 - $0.21+57.14%Beat+371.4%20 up, 0 downFeb 4, 2022$11.87M
    Sep 30, 2021$0.23$0.17$0.17 - $0.17+35.29%Beat+109.1%20 up, 0 downOct 29, 2021$10.91M
    Jun 30, 2021$0.14$0.15$0.04 - $0.15-6.67%Miss+180.0%2N/AJul 30, 2021$9.81M
    Mar 31, 2021$0.13$0.09$0.09 - $0.11+44.44%Beat-27.8%2N/AApr 30, 2021$9.22M
    Dec 31, 2020$0.07$0.09$0.09 - $0.12-22.22%Miss-76.7%2N/AFeb 4, 2021$8.55M
    Sep 30, 2020$0.11$0.05$0.05 - $0.15+120.00%Beat-52.2%2N/AOct 30, 2020$7.70M
    Jun 30, 2020$0.05-$0.04-$0.04 - $0.03+225.00%Beat-75.0%2N/AJul 30, 2020$6.79M
    Mar 31, 2020$0.18$0.12$0.12 - $0.18+50.00%Beat+38.5%2N/AApr 30, 2020$8.68M
    Dec 31, 2019$0.30$0.20$0.20 - $0.21+50.00%Beat+87.5%2N/AFeb 6, 2020$10.89M
    Sep 30, 2019$0.23$0.15N/A+53.33%Beat+64.3%2N/AOct 30, 2019$9.96M
    Jun 30, 2019$0.20$0.15$0.15 - $0.15+33.33%Beat+42.9%1N/AJul 30, 2019$9.23M
    Mar 31, 2019$0.13$0.13$0.13 - $0.170.00%In line+30.0%2N/AApr 30, 2019$8.44M
    Dec 31, 2018$0.16$0.13$0.13 - $0.13+23.08%Beat+60.0%2N/AFeb 6, 2019$8.34M
    Sep 30, 2018$0.14$0.10$0.10 - $0.10+40.00%Beat+100.0%2N/AOct 30, 2018$7.61M
    Jun 30, 2018$0.14$0.10$0.10 - $0.10+40.00%Beat+133.3%2N/AJul 31, 2018$7.38M
    Mar 31, 2018$0.10$0.06$0.06 - $0.06+66.67%BeatN/A2N/AApr 30, 2018$7.11M
    Dec 31, 2017$0.10$0.06$0.05 - $0.06+66.67%Beat-9.1%2N/AFeb 6, 2018$6.70M
    Sep 30, 2017$0.07$0.03N/A+133.33%Beat-50.0%N/AN/AOct 30, 2017$5.69M
    Jun 30, 2017$0.06$0.01N/A+500.00%Beat-75.0%N/AN/AJul 28, 2017$5.52M
    Mar 31, 2017-$0.02$0.01N/A-300.00%Miss-109.5%N/AN/AApr 28, 2017$5.16M
    Dec 31, 2016$0.11$0.04N/A+175.00%Beat-50.0%N/AN/AFeb 6, 2017$5.99M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.92, up 19.3% from the year before. It was $0.70 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.92+19.3%
    Dec 31, 2024$1.61+8.8%
    Dec 31, 2023$1.48+35.8%
    Dec 31, 2022$1.09+31.3%
    Dec 31, 2021$0.83+102.4%
    Dec 31, 2020$0.41-52.3%
    Dec 31, 2019$0.86+59.3%
    Dec 31, 2018$0.54+157.1%
    Dec 31, 2017$0.21-70.0%
    Dec 31, 2016$0.70N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8506
    2026Q2Jun 30, 20262,6544
    2026Q1Mar 31, 20262,6194
    2025Q4Dec 31, 20252,5245
    2025Q3Sep 30, 20252,6515
    2025Q2Jun 30, 20252,9015
    2025Q1Mar 31, 20252,5104
    2024Q4Dec 31, 20242,9105

    2026Q3 Earnings Call

    Opening remarks

    Roger Susi President and Chief Executive Officer Thank you. Good morning, and welcome to IRadimed's Third Quarter 2026 Earnings Call. I'm very proud to say that the new 3870 MR IV pump launch is showing itself to be everything we had hoped for and more. Though you may recall that we discussed the ramping of this new pump would be quite a stretch, we have been able to push very hard and make it happen. With our initial testing-of-the-waters release of a few dozen pumps during Q4 and Q1 to the broad market launch in Q2, and having produced now over 400 systems during Q3, our teams have risen to perform extraordinarily well. The job of ramping production of this complex electromechanical device at the rate achieved is a very difficult task, and these hard-working ladies and gentlemen of your company have really risen to the challenge. The ramp rate of the 3870 production to achieve Q3's revenue was huge, at over a 125% increase from Q2's production, thus the large stretch goal for production. And to support the goal was a great selling effort. Consider that during Q3, our sales team booked record numbers of both the 3880 monitor and 3870 pumps, proving the customer acceptance of these devices and building a very comfortable backlog for Q4. For Q4, we will again grow revenue of the new 3870 pump by another 50-plus percent. Again, very pleased to report that our teams have delivered. Here are the numbers. We achieved record quarterly revenue of $24.2 million, up 14% from Q3 of 2025 and an 18% sequential increase from Q2. Earnings were $0.51 per share GAAP and $0.55 non-GAAP, up from $0.41 and $0.46, respectively, in the second quarter. And as we expected, as our manufacturing teams climb the 3870 learning curve, we begin realizing efficiencies we had anticipated, with the gross margin improving 2 full points sequentially to 76%. Behind these quarter-end numbers is the performance of not only our production, engineering, quality and materials teams in-house, but our field sales team as well. We had concerns that the long-anticipated new 3870 pump could steal sales focus from the monitor, and so we put in place special targets to mitigate such an issue. Indeed, though Q1 did show weak monitor bookings, this was quickly turned around in Q2 with a record number of monitors booked, and we are once again extremely proud to note that record was exceeded again in Q3. In short, monitor sales are strong and growing. This is along with what is now clearly becoming a successful launch of the long-awaited 3870 MR IV pump.

    Frequently Asked Questions About IRMD

    When is Iradimed's next earnings date?

    Iradimed's next earnings report is expected for Feb 8, 2027.

    Did IRMD beat earnings estimates last quarter?

    No. Iradimed reported EPS of $0.51 for the quarter ended Sep 30, 2026, below the $0.52 estimate by 1.92%.

    What EPS do analysts expect from IRMD next quarter?

    The consensus EPS estimate for Iradimed for the quarter ending Dec 31, 2026 is $0.61 from 5 analysts, with estimates from $0.58 to $0.64.

    How often does IRMD beat earnings estimates?

    Iradimed beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.83%.